Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

“…Other treatments for such patients have not had beneficial effects over the long term and may not be well tolerated. [30][31][32][33] Our shortterm study suggests that anti-TNF-a therapy with cA2 may represent a new treatment option for patients with moderate-to-severe Crohn's disease. Further studies will be necessary to determine the longterm efficacy of a single infusion of cA2 as well as the efficacy and safety of repeated treatments.…”

Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis

“…Blood for GLP-2 RIA was collected in a final volume of 10% Trasylol, EDTA, Diprotin A (5,000 KIU/ml:32 mM:0.1 nM), and plasma was stored at Ϫ80°C before analysis by RIA (6). Semiquantitative RT-PCR was carried out with aliquots analyzed from a range (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) of cycle numbers to ensure linearity for mouse TGF-␣ mRNA as previously described (8,9,34). The PCR conditions were 94°C for 1 min and 68°C for 2 min for 30 cycles.…”

“…Although these latter agents are generally effective they do not specifically target the intestine and their side effects may be considerable, precluding longterm use in patients with chronic IBD. Newer targeted approaches to immunosuppressive and anti-inflammatory therapy, including use of monoclonal antibodies against lymphocyte antigens (24,48) or tumor necrosis factor (TNF) (46,50), interleukin-4 (IL-4) delivery via adenoviral gene transfer (29), and antisense oligonucleotides for suppression of intercellular adhesion molecule activity (ICAM), are currently under evaluation.…”

A Review of Inflammatory Bowel Disease in Patients with Human Immunodeficiency Virus Infection

“…Among these, CD4+ T lymphocytes have an important role in the pathogenesis of human IBD; this association is supported by the clinical effects of monoclonal anti CD4+ antibodies in patients with Crohn's disease [6]. Inflammatory bowel disease patients with concomitant leukemia when treated with bone marrow transplantation can remain in long-term remissions, suggesting that the host immune dysregulation has an important role in the perpetuation of this disease [7].…”